Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

(2012) Jack Antel et al.   ACTA NEUROPATHOLOGICA

Immunological Markers of Optimal Response to Natalizumab in Multiple Sclerosis

(2012) Luisa M. Villar   ARCHIVES OF NEUROLOGY

Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions

(2012) María C. Sádaba et al.   JOURNAL OF NEUROIMMUNOLOGY

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

(2012) Markus C Kowarik et al.   Journal of Neuroinflammation

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

(2012) A Harrer et al.   Multiple Sclerosis Journal

Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression

(2012) Pedro Lourenco et al.   Multiple Sclerosis Journal

Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions

(2012) Ayumi Yoshizaki et al.   NATURE

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual

(2011) Laurence Durante et al.   Multiple Sclerosis Journal

Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes

(2011) Maria José Magraner et al.   NEURORADIOLOGY

Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

(2010) Laura Piccio et al.   ARCHIVES OF NEUROLOGY

Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis

(2010) Luisa M. Villar et al.   CLINICAL IMMUNOLOGY

Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM

(2010) Patrizia Sola et al.   Multiple Sclerosis Journal

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses

(2008) Koichi Yanaba et al.   IMMUNITY

Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis

(2008) M Thangarajh et al.   Multiple Sclerosis Journal